Genitourinary Radiology: Page 8

PET tracer shows promise in prostate cancer patients
By Will Morton
Gallium-68 RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented at RSNA 2023.
November 26, 2023
An image showing potentially different sites of PET radiotracer uptake by prostate cancer tumors between U.S. approved Ga-68 PSMA-PET and experimental Ga-68 RM2. Image courtesy of Heying Duan, MD, Stanford University.
Elastography predicts treatment response in colorectal cancer patients
By Amerigo Allegretto
Elastography could help with treatment strategies for colorectal cancer patients, a study presented November 26 at the RSNA annual meeting found.
November 26, 2023
Jae Seok Bae, MD, from Seoul National University Hospital presented research at RSNA showing the efficacy of shear-wave elastography in predicting chemotherapy response in colorectal patients.
Features found on MRI may predict liver cancer recurrence after surgery
By Kate Madden Yee
An algorithm based on MRI features could help clinicians predict liver cancer recurrence after patients have undergone liver resection, researchers have found.
November 8, 2023
Preoperative axial extracellular contrast agent-enhanced (A-E) MRI and (F-H) follow-up CT images in a 71-year-old male patient with chronic hepatitis B and a serum neutrophil count of 4.2 × 109/L. A 5.6-cm mass with a 1.9-cm satellite nodule was detected in segments V and VIII. (A) The mass (asterisks, A-E) shows mild-to-moderate hyperintensity on T2-weighted images, (B) hypointensity on T1-weighted noncontrast-enhanced images, (C) less than 50% hyperenhancement on late arterial phase images, (D) nonperipheral washout and incomplete enhancing capsule on portal venous phase images, and (E) marked diffusion restriction on diffusion-weighted images (b = 800 sec/mm2). The mass was confirmed at histopathologic analysis as moderately differentiated hepatocellular carcinoma with microvascular invasion. With an advanced-stage recurrence after resection score of 19.8 points (4.2 + 5.6 + 10), this patient was assigned to the high-risk group (≥15 points) for advanced-stage recurrence. At follow-up, (F) noncontrast-enhanced, (G) arterial phase, and (H) portal venous phase CT images acquired at day 70 after surgery show multifocal intrahepatic recurrence and tumor thrombus in the left portal vein (black arrow, H). Images and caption courtesy of the RSNA.
PET/CT-based model predicts prostate cancer in the 'PSA grey zone'
By Will Morton
Combining PET/CT with traditional clinical risk factors can detect prostate cancer in cases considered borderline based on prostate-specific antigen (PSA) levels -- in other words, cases in the "PSA grey zone," according to a group in Hunan, China.
September 10, 2023
2023 09 08 15 10 4007 2023 09 08 Prostate Cancer 20230908154926
COVID-19 pandemic led to apparent decreases in cancer incidence
By Amerigo Allegretto
The COVID-19 pandemic led to apparent decreases in cancer incidence for several cancer types, suggest Canadian findings published September 5 in JAMA Network Open.
September 5, 2023
2023 09 05 21 24 9441 Covid 19 Second Wave 400
PET/CT and PET/MRI appear equivalent for diagnosing prostate cancer
By Will Morton
PET/CT and PET/MRI have gone head-to-head for detecting prostate cancer relapse in a review that included 37 clinical studies and 8,709 patients -- with PET/MRI taking a slight lead, according to a team in China.
August 31, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
CLS Americas inks partnership with Focalyx
By AuntMinnie.com staff writers
Clinical Laserthermia Systems (CLS) Americas has inked a comarketing agreement with Focalyx for image-guided focal laser ablation of prostate tumors.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Are PSMA-PET tracers equal in detecting prostate cancer?
By Will Morton
Researchers in China have provided some clarity for clinicians over which prostate-specific membrane antigen (PSMA) radiotracer may be best for PET/CT prostate cancer imaging, according to a study published August 21 in Cancer Imaging.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Telix posts 2023 half-year report
By AuntMinnie.com staff writers
Telix Pharmaceuticals reported a spike in revenue for the first half of 2023, citing strong sales of its Illucix kit for preparing gallium-68 gozetotide injections for PET prostate cancer imaging.
August 22, 2023
2016 12 23 14 10 03 523 Graph Bar Arrow Up 400
AI developed for SPECT kidney imaging in children
By Will Morton
An AI model based on SPECT images has the potential to help nuclear medicine physicians identify kidney defects in children, according to a research group in Taiwan.
August 16, 2023
2016 08 23 17 04 30 620 Kidney 400
Clarity advances dose escalation for cohort in SECuRE trial
By AuntMinnie.com staff writers
Radiopharmaceutical developer Clarity Pharmaceuticals is highlighting the completion of the second cohort, as well as the advancement to the third cohort in the dose escalation phase of its phase I/II theranostic trial, SECuRE.
August 9, 2023
2021 01 16 00 14 5464 Prostate Cancer 400
MRI fusion-targeted plus systematic biopsy identifies prostate cancer
By Kate Madden Yee
The combination of ultrasound and MRI fusion-targeted biopsies with systematic biopsies is more effective for identifying suspicious lesions than systematic biopsies alone, a study published July 25 in Radiology has found.
July 25, 2023
2023 07 25 21 31 5449 2023 07 25 Radiology Wei Figure4 20230725212024
Previous Page
Page 8 of 96
Next Page